

### Final Appraisal Recommendation

Advice No: 0417 – February 2017

**Triptorelin (Decapeptyl® SR) 3 mg and 11.25 mg powder for suspension for injections, 22.5 mg powder and solvent for suspension for injection**

**Limited submission by Ipsen Ltd**

### Recommendation of AWMMSG

**Triptorelin (Decapeptyl® SR) is recommended as an option for use within NHS Wales as an adjuvant treatment to radiotherapy in patients with high-risk localised or locally advanced prostate cancer and as neoadjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer.**

#### Additional note(s):

- Please refer to the Summary of Product Characteristics for the full licensed indication.

In reaching the above recommendation AWMMSG has taken account of the appraisal documentation prepared by the AWMMSG Secretariat (reference number 1658), which includes the AWMMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 1658:  
Triptorelin (Decapeptyl® SR) 3 mg and 11.25 mg powder for suspension for injection, 22.5 mg powder and solvent for suspension for injection. February 2017.